PMC Group International Announces Acquisition of Pharma Company in France

On Dec 5, 2017

PMC Group France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of Mount Laurel-based PMC Group Inc., announced the acquisition of the pharma business of Isochem SAS of France. This is a fully integrated business comprised of research, product/process development, regulatory approvals, pilot scale and full plant-scale production of drug intermediates and active pharma ingredients (APIs) for major pharmaceutical companies worldwide to serve the needs of Oncology, Cardiovascular, Infectious, Gastro-Intestinal, Neurology and rare diseases. These facilities with combined footprint of over 40 acres are located at three sites — Gennevilliers, Pithiviers, and Vert-Le-Petit — within a 60 miles radius of Paris. The facilities, which are all cGMP US-FDA audited plants for manufacturing pharmaceutical products, will henceforth forth be called “PMC Isochem SAS” and the latter with 230+ employees will operate as a wholly owned subsidiary of PMC Group France.

“This acquisition, coming within two months of the acquisition of the Hyderabad, India-based pharma company YM Drugs and Chemicals by PMC Group International, puts the latter in a solid position to serve all the regulated pharma markets around the world with cost-effective offerings of proprietary drugs, drug intermediates, and custom drug research & manufacturing services for a wide range of disease categories,” said Dr. Raj Chakrabarti, Executive Vice President of PMC Group International.

Related Articles: